CN113646046B - 五环化合物的盐及其晶体 - Google Patents

五环化合物的盐及其晶体 Download PDF

Info

Publication number
CN113646046B
CN113646046B CN202080014060.2A CN202080014060A CN113646046B CN 113646046 B CN113646046 B CN 113646046B CN 202080014060 A CN202080014060 A CN 202080014060A CN 113646046 B CN113646046 B CN 113646046B
Authority
CN
China
Prior art keywords
thieno
crystals
diffraction
powder
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080014060.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN113646046A (zh
Inventor
吉田贤史
大桥芳章
星川环
佐藤信明
栉田郁雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN113646046A publication Critical patent/CN113646046A/zh
Application granted granted Critical
Publication of CN113646046B publication Critical patent/CN113646046B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202080014060.2A 2019-03-05 2020-03-03 五环化合物的盐及其晶体 Active CN113646046B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019039349 2019-03-05
JP2019-039349 2019-03-05
PCT/JP2020/008889 WO2020179781A1 (ja) 2019-03-05 2020-03-03 五環式化合物の塩およびそれらの結晶

Publications (2)

Publication Number Publication Date
CN113646046A CN113646046A (zh) 2021-11-12
CN113646046B true CN113646046B (zh) 2024-05-17

Family

ID=72337486

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080014060.2A Active CN113646046B (zh) 2019-03-05 2020-03-03 五环化合物的盐及其晶体

Country Status (11)

Country Link
US (1) US11420980B2 (https=)
EP (1) EP3936189A4 (https=)
JP (1) JP7508441B2 (https=)
KR (1) KR102921161B1 (https=)
CN (1) CN113646046B (https=)
AU (1) AU2020233452B2 (https=)
BR (1) BR112021015979A2 (https=)
CA (1) CA3129764A1 (https=)
MX (1) MX2021009774A (https=)
TW (2) TWI870286B (https=)
WO (1) WO2020179781A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020179780A1 (ja) 2019-03-05 2020-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 五環式複素環化合物
PT119624A (pt) * 2024-07-29 2026-01-29 Silva Escada Guilherme Máquina modular para a dobragem de tubos de pvc

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859016A (en) * 1995-06-20 1999-01-12 Je Il Pharmaceutical Co., Ltd. Memory enhancing and anti-dementia agent containing dehydroevodiamine HC1 as active ingredient

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187306A (en) * 1977-07-26 1980-02-05 Bayer Aktiengesellschaft Benzodiazepine-diones, a process for their production and their use as medicaments
DD258234A1 (de) 1987-03-05 1988-07-13 Univ Leipzig Verfahren zur herstellung von pyrido/3',2':4,5/thieno/2,3-e/imidazo-/1,2-c/pyrimidinen sowie strukturanaloger -pyrimido/1,2-c/pyrimidine bzw. -1,3-diazepino/1,2-c/pyrimidine
RU2117670C1 (ru) 1988-10-31 1998-08-20 Эйсай Ко., Лтд. Производные триазоло[1,4]диазепина и способы их получения
TW197442B (https=) * 1990-02-08 1993-01-01 Pfizer
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
CL2004000348A1 (es) 1997-04-15 2005-01-14 Cephalon Inc & Kyowa Hakko Kog Compuesto derivado de estaurosporina bis-n-sustituida, util para potenciar la funcion de neuronas colinergicas, estriadas, del prosencefalo basal y sensoriales.
CL2004000352A1 (es) 1998-05-26 2005-05-27 Cephalon Inc & Kyowa Hakko Kog Uso de compuestos derivados de estaurosporina para potenciar la funcion de neuronas colinergicas, estriadas, de prosencefalo basal y sensoriales.
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
US8252520B2 (en) 2002-10-11 2012-08-28 Taivex Therapeutics Corporation Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases
AU2005299031B2 (en) 2004-10-20 2011-11-10 F. Hoffmann-La Roche Ag Halogen substituted benzodiazepine derivatives
US9314318B2 (en) * 2008-08-26 2016-04-19 Zest Ip Holdings, Llc Dental anchor apparatus and method
JP6557441B1 (ja) * 2017-09-07 2019-08-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 五環式化合物
WO2020179780A1 (ja) 2019-03-05 2020-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 五環式複素環化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859016A (en) * 1995-06-20 1999-01-12 Je Il Pharmaceutical Co., Ltd. Memory enhancing and anti-dementia agent containing dehydroevodiamine HC1 as active ingredient

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HEMDAN Magdy Mohamed, et al..Uses of 1-(3-Cyano-4,5,6,7-tetrahydrobenzo[b]-thiophen-2-yl)-3- dodecanoylthiourea as a Building Block in the Synthesis of Fused Pyrimidine and Thiazine Systems.Chem. Pharm. Bull. .第63卷(第6期),450-456. *

Also Published As

Publication number Publication date
EP3936189A1 (en) 2022-01-12
JP7508441B2 (ja) 2024-07-01
BR112021015979A2 (pt) 2021-10-05
KR20210135223A (ko) 2021-11-12
US11420980B2 (en) 2022-08-23
CN113646046A (zh) 2021-11-12
KR102921161B1 (ko) 2026-02-02
TWI849070B (zh) 2024-07-21
MX2021009774A (es) 2021-09-08
JPWO2020179781A1 (https=) 2020-09-10
AU2020233452A1 (en) 2021-09-02
EP3936189A4 (en) 2022-12-14
TW202430531A (zh) 2024-08-01
WO2020179781A1 (ja) 2020-09-10
AU2020233452B2 (en) 2025-04-10
TW202100531A (zh) 2021-01-01
US20210024541A1 (en) 2021-01-28
TWI870286B (zh) 2025-01-11
CA3129764A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
CN117886813A (zh) Shp2磷酸酶变构抑制剂
RU2754557C1 (ru) Пентациклическое соединение
CN110914277B (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
CN113646046B (zh) 五环化合物的盐及其晶体
CN114149432A (zh) 用于癌症治疗的双重clk/cdk1抑制剂
RU2820938C2 (ru) Соль пентациклического соединения и его кристалл
EP1001956B1 (en) 2,3-benzodiazepine derivatives
KR102352624B1 (ko) LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물
HK40022802B (en) Pentacyclic compound
HK40022802A (en) Pentacyclic compound
HK1201266B (en) Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors
HK1192233B (en) Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors
HK1201266A1 (zh) 作为parp抑制剂的稠合的四元或五元环吡啶并酞嗪酮类化合物
HK1192233A1 (zh) 作为parp抑制剂的稠合的四环或五环的二氢二氮杂䓬并咔唑酮

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant